PPIB and metastatic melanoma: However, dasatinib treatment can also increase the expression of a different biomarker called glycoprotein non-metastatic melanoma B (gpNMB), in which high levels of gpNMB on the surface of TNBC cells is associated with lower overall survival of patients.